Quality-adjusted life years

Practical Neurology

Volumn 8, Issue 3, 2008, Pages 175-182

  Vergel, Yolanda Bravo ^a   Sculpher, Mark ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HEALTH SERVICES RESEARCH; HEALTH STATUS; HUMAN; PAIN ASSESSMENT; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; STANDARD;

HEALTH SERVICES RESEARCH; HEALTH STATUS; HUMANS; PAIN MEASUREMENT; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 45449111013     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/pn.2007.140186     Document Type: Article

References (27)

1. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines-similarities, differences and some implications. Value Health 2001;4:225-50.
2. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2004.
3. Manca A, Sculpher MJ, Ward K, et al. A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG 2003;110:255-62.
4. Drummond M, Sculpher M, Torrance G, et al. Methods of the economic evaluation of health care programmes, Third edition. Oxford: Oxford University Press, 2005.
5. Logan AG, Milne BJ, Achber C, et al. Cost-effectiveness of a worksite hypertension treatment programme. Hypertension 1981; 3:211-18.
6. Hull RD, Hirsh J, Sackett DL, et al. Cost-effectiveness of clinical diagnosis, venography and non-invasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med 1981; 304:1561-7.
7. Sculpher MJ, Buxton MJ. The episode-free days as a composite measure of effectiveness. Pharmacoeconomics 1993;4:345-52.
8. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
9. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323:1300-3.
10. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21.
11. Manca A, Hawkins N, Sculpher M. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96.
12. Torrance G, Feeny D, Furlong W. Visual analogue scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001;21:329-34.
13. Bleichrodt H, Johannesson M. An experimental test of a theoretical foundation for rating scale valuations. Med Decis Making 1997; 17:208-16.
14. Tengs T, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
15. Stein K, Fry A, Round A, et al. What value health? A review of health state values used in early technology assessments for NICE. Appl Health Econ Health Policy 2005;4:219-28.
16. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Second edition. Philadelphia: Lippincott-Raven, 1996:191-201.
17. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21:271-92.
18. Furlong WJ, Feeny DH, Torrance GW, et al. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-84.
19. Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
20. Kind P. Issues in the design and construction of a quality of life measure. In Baldwin S, et al. Quality of life: perspective and policies. London, UK: Routledge, 1990.
21. Brooks R with the EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
22. Dolan P, Gudex C, Kind P, et al. A social tariff for EuroQol: results from a UK general population survey. Discussion Paper No 138, Centre for Health Economics, University of York, 1995.
23. Williams A. Intergenerational equity: an exploration of the 'fair innings' argument. Health Econ 1997;6:117-32.
24. Williams A. If we are going to get a fair innings, someone will need to keep the score! In: Barer ML, Getzen TE, Stoddart GL, eds. Health, health care and health economics. New York: Wiley, 1998.
25. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003;326:522-8.
26. Noyes K, Dick A, Holloway R. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomised clinical-economic trial. Med Decis Making 2004;24:472-85.
27. Forbes R, MacDonald S, Eljamel S, et al. Cost-utility analysis of vagus nerve stimulators for adults with medically refractory epilepsy. Seizure 2003;12:249-56.